Icatibant Teva (Icatibant Acetate)

Icatibant acetate is a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause the sudden swelling in HAE.

The dosage regimen for Icatibant Teva is determined by the prescribing clinician based on the patient’s condition, severity of the attack, and clinical guidelines. The prescriber will specify the exact amount and frequency of administration.

Safety data for icatibant acetate in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Icatibant Teva is a bradykinin B2 receptor antagonist, whereas other approved HAE therapies include C1‑esterase inhibitor concentrates and kallikrein inhibitors. Icatibant acts directly at the receptor level, offering rapid subcutaneous administration, while alternatives may be given intravenously or have different mechanisms.

Icatibant Teva should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

The medication is supplied as a solution for injection and is administered subcutaneously, typically into the abdomen or thigh. Healthcare professionals should follow aseptic technique, use the appropriate needle size, and observe the patient for any immediate adverse reactions after injection.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, marked hypotension, and rare cases of thrombocytopenia. Patients should be monitored closely after the first dose, and any signs of severe allergic response require immediate medical attention.

Icatibant Teva is contraindicated in individuals with known hypersensitivity to icatibant acetate or any of its excipients. Caution is also advised for patients with unstable cardiovascular disease, and it should be avoided in those receiving ACE inhibitors or neprilysin inhibitors unless clinically justified.